JP2007525183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007525183A5 JP2007525183A5 JP2006514206A JP2006514206A JP2007525183A5 JP 2007525183 A5 JP2007525183 A5 JP 2007525183A5 JP 2006514206 A JP2006514206 A JP 2006514206A JP 2006514206 A JP2006514206 A JP 2006514206A JP 2007525183 A5 JP2007525183 A5 JP 2007525183A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- protein
- seq
- polynucleotide
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46700203P | 2003-04-30 | 2003-04-30 | |
| PCT/US2004/013568 WO2004098515A2 (en) | 2003-04-30 | 2004-04-30 | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011023063A Division JP2011152132A (ja) | 2003-04-30 | 2011-02-04 | 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007525183A JP2007525183A (ja) | 2007-09-06 |
| JP2007525183A5 true JP2007525183A5 (https=) | 2007-10-18 |
Family
ID=33435005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006514206A Pending JP2007525183A (ja) | 2003-04-30 | 2004-04-30 | 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質 |
| JP2011023063A Pending JP2011152132A (ja) | 2003-04-30 | 2011-02-04 | 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011023063A Pending JP2011152132A (ja) | 2003-04-30 | 2011-02-04 | 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1622571A4 (https=) |
| JP (2) | JP2007525183A (https=) |
| AU (2) | AU2004235755A1 (https=) |
| CA (1) | CA2522994C (https=) |
| WO (1) | WO2004098515A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7117033B2 (en) | 2000-05-08 | 2006-10-03 | Brainsgate, Ltd. | Stimulation for acute conditions |
| US7561919B2 (en) | 2002-11-14 | 2009-07-14 | Brainsgate Ltd. | SPG stimulation via the greater palatine canal |
| US9233245B2 (en) | 2004-02-20 | 2016-01-12 | Brainsgate Ltd. | SPG stimulation |
| US8010189B2 (en) | 2004-02-20 | 2011-08-30 | Brainsgate Ltd. | SPG stimulation for treating complications of subarachnoid hemorrhage |
| US8055347B2 (en) | 2005-08-19 | 2011-11-08 | Brainsgate Ltd. | Stimulation for treating brain events and other conditions |
| US20070248535A1 (en) * | 2005-02-07 | 2007-10-25 | The Trustees Of Columbia University In The City Of New York | Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity |
| NZ571568A (en) * | 2006-03-31 | 2010-11-26 | Alnylam Pharmaceuticals Inc | Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene |
| JP6236948B2 (ja) * | 2013-07-17 | 2017-11-29 | 東ソー株式会社 | 抗体精製用溶出液および当該溶出液を用いた抗体精製方法 |
| EP2878335B1 (en) | 2013-11-10 | 2018-01-03 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2016170541A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| EP3865139B1 (en) | 2015-02-18 | 2023-05-03 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US10271907B2 (en) | 2015-05-13 | 2019-04-30 | Brainsgate Ltd. | Implant and delivery system for neural stimulator |
| CN109069539A (zh) | 2016-02-18 | 2018-12-21 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
| TWI795381B (zh) * | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US12269813B2 (en) | 2019-02-22 | 2025-04-08 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate |
| EP3953345B1 (en) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Pyridine rings containing derivatives as malt1 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2399776A1 (en) * | 2000-02-03 | 2001-08-09 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| WO2002083921A2 (en) * | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
-
2004
- 2004-04-30 WO PCT/US2004/013568 patent/WO2004098515A2/en not_active Ceased
- 2004-04-30 AU AU2004235755A patent/AU2004235755A1/en not_active Abandoned
- 2004-04-30 JP JP2006514206A patent/JP2007525183A/ja active Pending
- 2004-04-30 CA CA2522994A patent/CA2522994C/en not_active Expired - Fee Related
- 2004-04-30 EP EP04760669A patent/EP1622571A4/en not_active Withdrawn
-
2008
- 2008-09-05 AU AU2008212020A patent/AU2008212020B2/en not_active Ceased
-
2011
- 2011-02-04 JP JP2011023063A patent/JP2011152132A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007525183A5 (https=) | ||
| JP6182127B2 (ja) | 腫瘍において示差的に発現する遺伝子産物およびその利用 | |
| JP6223488B2 (ja) | 腫瘍で差次的に発現する遺伝子産物及びその用途 | |
| CN105837689B (zh) | 抗cd19单克隆抗体及其制备方法 | |
| CA2395053A1 (en) | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof | |
| US20190194345A1 (en) | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer | |
| JP2016094485A (ja) | 新規モジュレータ及びその使用法 | |
| US9683032B2 (en) | Anti-S100A4 antibody molecules and their uses | |
| US9453070B2 (en) | Methods for detecting Th1 cells | |
| Fry et al. | CD22-CAR T cells induce remissions in CD19-CAR naïve and resistant B-ALL | |
| WO2000053758A2 (en) | Compositions and methods for the treatment of immune related diseases | |
| JP2014528714A5 (https=) | ||
| JP2007504280A5 (https=) | ||
| JPWO2016002189A1 (ja) | 抗プログルカゴン抗体 | |
| JP2006519774A (ja) | 癌の治療のための組成物と方法 | |
| CN112812179B (zh) | 高亲和力高特异性抗cmtm6单克隆抗体及其用途 | |
| JP2003520605A5 (https=) | ||
| JP7821779B2 (ja) | 抗体を使用した細胞表面ｍｉｃａ及びｍｉｃｂの検出 | |
| Liu et al. | Generation and characterization of mAb 61H9 against junctional adhesion molecule-a with potent antitumor activity | |
| Bao et al. | Cloning, expression, monoclonal antibody preparation of human gene NBEAL1 and its application in targeted imaging of mouse glioma | |
| WO2012160031A1 (en) | Method for prognosing solid tumor outcome | |
| WO2010123119A1 (ja) | 炎症性腸疾患治療剤およびそのスクリーニング方法 | |
| JP2008532923A (ja) | 抗ｇｆｒａ１抗体のエフェクター機能を用いて細胞を障害する方法 | |
| KR20190107967A (ko) | 한국인 위암 연관 유전자 단클론 항체 및 이의 제조방법 | |
| NZ708615B2 (en) | Novel modulators and methods of use |